Misetionamide Pipeline

Broad applicability & potential.

Misetionamide, our lead asset, is a broadly active small molecule with a unique mechanism of action that inhibits two oncogenic transcription factors, c-MYC and NFκB. Acting through c-MYC, misetionamide selectively disrupts the energy metabolism of cancer cells leading to cancer cell death. Through NFκB inhibition, misetionamide inhibits cancer cells’ ability to proliferate and survive. ​

This powerful anti-cancer, dual-target mechanism of action makes misetionamide an attractive tumor cell selective agent across many cancers.​